Perioperative Treatment in Gastric Cancer: A Fast-Changing Field.

Cancers (Basel)

Medical Oncology Department, Pedro Hispano Hospital, 4464-513 Matosinhos, Portugal.

Published: December 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Gastric cancer is the fifth most common cancer worldwide and its incidence is rising. Surgery is the only curative strategy and its association with perioperative chemotherapy is now standard treatment for most resectable tumors. Despite treatment advances, disease relapse is high, even in early stages, and continued improvement in curative treatment is imperative. With deeper knowledge of gastric cancer heterogeneity, molecular subtypes, and the tumor immune microenvironment, new standard treatment strategies may emerge in the near future. This paper provides a comprehensive review of the current treatment landscape in resectable gastric cancer and future perspectives for the next decade regarding new agents such as targeted therapies, immunotherapy, antibody-drug conjugates, and the combination of multiple treatment modalities.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11640278PMC
http://dx.doi.org/10.3390/cancers16234036DOI Listing

Publication Analysis

Top Keywords

gastric cancer
16
standard treatment
8
treatment
6
cancer
5
perioperative treatment
4
gastric
4
treatment gastric
4
cancer fast-changing
4
fast-changing field
4
field gastric
4

Similar Publications

Background: Gastric cancer epidemiology evolved rapidly in the last century, shifting from being one of the main causes of cancer-related death to the sixth in high-income countries.

Methods: We conducted a narrative review on gastric cancer epidemiology. Our review focused on trends of gastric cancer and its relationship with Helicobacter pylori infection; cardia and noncardia gastric cancer risk factors; early onset gastric cancer; second primary cancers in patients with gastric cancer; and implementation of gastric cancer prevention strategies.

View Article and Find Full Text PDF

Objective: To evaluate the burden and trends of digestive system cancers in adolescents and young adults (AYAs) globally between 1990 and 2021.

Methods: Data were extracted from the Global Burden of Diseases, Injuries, and Risk Factors Study (1990-2021). We analyzed global, regional, and national disease burdens by calculating the age-standardized incidence (ASIR), mortality (ASMR), and disability-adjusted life years (DALYs) for AYAs.

View Article and Find Full Text PDF

NSUN6 Promotes Gastric Cancer Progression by Stabilizing CEBPZ mRNA in a mC-Dependent Manner.

Appl Biochem Biotechnol

September 2025

Operating Room, Shanghai Tianyou Hospital, No.528, Zhennan Road, Putuo District, Shanghai, 200331, China.

Gastric cancer (GC) is a malignant tumor originating from the epithelial cells of the gastric mucosa. The 5-methylcytosine (mC) modification refers to the addition of a methyl group to the fifth carbon atom of cytosine in RNA molecules. This study aimed to investigate the role of NOL1/NOP2/SUN domain (NSUN)6 in GC and its underlying molecular mechanisms.

View Article and Find Full Text PDF

Background: The association between preoperative liver function and short-term outcomes after gastrointestinal cancer surgery is unknown. This study investigated the impact of Child-Pugh score-based preoperative liver dysfunction on short-term outcomes after distal gastrectomy and right hemicolectomy.

Materials And Methods: We included patients who underwent distal gastrectomy for gastric cancer or right hemicolectomy for colon cancer between 2018 and 2022 from the Japanese National Clinical Database.

View Article and Find Full Text PDF